中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物化学研究室
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

文献类型：期刊论文

作者Wang, Ying-Qing1; Wang, Ping-Yuan2,3,4; Wang, Yu-Ting1; Yang, Guang-Fu4; Zhang, Ao2,3; Miao, Ze-Hong1
刊名JOURNAL OF MEDICINAL CHEMISTRY
出版日期2016-11-10
卷号59期号:21页码:9575-9598
ISSN号0022-2623
DOI10.1021/acs.jmedchem.6b00055
文献子类Article
英文摘要Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting, homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on, the above advances.
WOS关键词NEGATIVE BREAST-CANCER ; ADVANCED SOLID TUMORS ; SEROUS OVARIAN-CANCER ; DNA-DAMAGE RESPONSE ; CELL LUNG-CANCER ; OLAPARIB MAINTENANCE THERAPY ; RIBOSE POLYMERASE INHIBITOR ; CYCLIN-DEPENDENT KINASE-5 ; BRCA MUTATION CARRIERS ; PHASE-I TRIAL
资助项目National Basic Research Program of China[2012CB932502] ; National Basic Research Program of China[2015CB910603] ; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" of China[2016ZX09101009] ; National Natural Science Foundation of China[81573450] ; National Natural Science Foundation of China[81321092] ; National Natural Science Foundation of China[81430080] ; Chinese Academy of Sciences[XDA12020104] ; Chinese Academy of Sciences[CASIMM0120152003] ; Chinese Academy of Sciences[CASIMM0120153005] ; Chinese Academy of Sciences (Hundred Talents Project)[00000000] ; Science and Technology Commission of Shanghai Municipality[16JC1406300] ; Science and Technology Commission of Shanghai Municipality[14431905300] ; State Key Laboratory of Drug Research[SIMM1601ZZ-03]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000387737600001
出版者AMER CHEMICAL SOC
源URL[http://119.78.100.183/handle/2S10ELR8/275814]  
专题药物化学研究室
中科院受体结构与功能重点实验室
新药研究国家重点实验室
药理学第一研究室
通讯作者Zhang, Ao; Miao, Ze-Hong
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China;
2.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Lu,Bldg 3,Room 426, Shanghai 201203, Peoples R China;
3.Chinese Acad Sci, Shanghai Inst Mat Med, Synthet Organ & Med Chem Lab, 555 Zuchongzhi Lu,Bldg 3,Room 426, Shanghai 201203, Peoples R China;
4.Cent China Normal Univ, Coll Chem, Key Lab Pesticide & Chem Biol, Minist Educ, Wuhan 430079, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Ying-Qing,Wang, Ping-Yuan,Wang, Yu-Ting,et al. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy[J]. JOURNAL OF MEDICINAL CHEMISTRY,2016,59(21):9575-9598.
APA Wang, Ying-Qing,Wang, Ping-Yuan,Wang, Yu-Ting,Yang, Guang-Fu,Zhang, Ao,&Miao, Ze-Hong.(2016).An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.JOURNAL OF MEDICINAL CHEMISTRY,59(21),9575-9598.
MLA Wang, Ying-Qing,et al."An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy".JOURNAL OF MEDICINAL CHEMISTRY 59.21(2016):9575-9598.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。